Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections

Ooms, F.; Wouters, J.; Oscari, O.; Happaerts, T.; Bouchard, Géraldine; Carrupt, Pierre-Alain; Testa, Bernard; Lambert, D. M.

doi:10.1021/jm020995r

Scientific article

English

Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections

ContributorsOoms, F.; Wouters, J.; Oscari, O.; Happaerts, T.; Bouchard, Géraldine; Carrupt, Pierre-Alain; Testa, Bernard; Lambert, D. M.

Published inJournal of medicinal chemistry, vol. 45, no. 21, p. 4799-4799

Publication date2002

Affiliation entities

Not a UNIGE publication

Citation (ISO format)

OOMS, F. et al. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections. In: Journal of medicinal chemistry, 2002, vol. 45, n° 21, p. 4799–4799. doi: 10.1021/jm020995r

Article

Identifiers

PID : unige:10620
DOI : 10.1021/jm020995r

Journal ISSN0022-2623

569views

0downloads

Creation06/08/2010 13:48:45

First validation06/08/2010 13:48:45

Update14/03/2023 16:00:27

Status update14/03/2023 16:00:26

Last indexation29/10/2024 16:38:00

Archive ouverte UNIGE

Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections

Technical informations